Background: Specific Major Depressive Disorder (MDD) biomarkers could help improve our understanding of MDD pathophysiology and aid in the refinement of current MDD criteria. While salivary cortisol (SC) can differentiate between healthy controls and patients with psychiatric disorders, salivary alpha amylase (sAA), may be a putative candidate biomarker for MDD specifically.
Methods: In a naturalistic cohort of consecutive out-patients and healthy controls, sAA and SC were determined in 833 participants (97 MDD patients, 142 patients with other mood, anxiety, and/or somatoform (MAS-) disorders, and 594 healthy controls). Samples were collected at 7 different time points (at awakening, after 30, 45, and 60 min, at 10:00 p.m., at 11:00 p.m., and at awakening on day 2).
Results: The mean age of the sample was 43.8 years (SD = 12.9; 63.9% female). Concerning sAA, MDD patients had higher sAA levels upon awakening on two consecutive days (p = 0.04, p = 0.01 respectively), as well as a higher area under the curve with respect to the increase (AUCi; p = 0.04) in comparison to both controls and the other MAS-disorders group. Regarding SC, mean levels of evening SC were elevated in MDD patients (p = 0.049) in comparison to both controls and the other MAS-disorders group. SC values on day 2 after ingestion of dexamethasone were elevated in both MDD patients and the other MAS-disorders group (p = 0.04, p = 0.047 respectively).
Conclusions: sAA at awakening and not cortisol differentiates MDD from other psychiatric disorders in outpatients. This suggests that sAA may be a valuable candidate biomarker specifically for MDD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.psyneuen.2018.07.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of psilocybin on mouse brain microstructure.
AJNR Am J Neuroradiol
January 2025
From the Department of Radiology (P.C.F., A.P.S., J.J.Y.).
Background And Purpose: There is surging interest in the therapeutic potential of psychedelic compounds like psilocybin in the treatment of psychiatric illnesses like major depressive disorder (MDD). Recent studies point to the rapid antidepressant effect of psilocybin; however, the biological mechanisms underlying these differences remain unknown. This study determines the feasibility of using diffusion MRI to characterize and define the potential spatiotemporal microstructural differences in the brain following psilocybin treatment in C57BL/6J male mice.
View Article and Find Full Text PDFSerum KNG and FVIII may serve as potential biomarkers for depression.
Behav Brain Res
January 2025
Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, PR China; Department of Psychiatry and Institute of Neuropsychiatry, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, PR China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan, 430071, China. Electronic address:
Background: The global burden of major depressive disorder (MDD) is rising, with current diagnostic methods hindered by significant subjectivity and low inter-rater reliability. Several studies have implied underlying link between coagulation-related proteins, such as kininogen (KNG) and coagulation factor VIII (FVIII), and depressive symptoms, offering new insights into the exploration of depression biomarkers. This study aims to elucidate the roles of KNG and FVIII in depression, potentially providing a foundational basis for biomarker research in this field.
View Article and Find Full Text PDFEEG-derived brainwave patterns for depression diagnosis via hybrid machine learning and deep learning frameworks.
Appl Neuropsychol Adult
January 2025
Faculty Xavier Institute of Engineering, Mahim, India.
In the fields of engineering, science, technology, and medicine, artificial intelligence (AI) has made significant advancements. In particular, the application of AI techniques in medicine, such as machine learning (ML) and deep learning (DL), is rapidly growing and offers great potential for aiding physicians in the early diagnosis of illnesses. Depression, one of the most prevalent and debilitating mental illnesses, is projected to become the leading cause of disability worldwide by 2040.
View Article and Find Full Text PDFDeep immunophenotyping of circulating immune cells in major depressive disorder patients reveals immune correlates of clinical course and treatment response.
Brain Behav Immun Health
February 2025
Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, University of Eastern Piedmont, 28100, Novara, Italy.
Major Depressive Disorder (MDD) is a widespread psychiatric condition impacting social and occupational functioning, making it a leading cause of disability. The diagnosis of MDD remains clinical, based on the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria, as biomarkers have not yet been validated for diagnostic purposes or as predictors of treatment response. Traditional treatment strategies often follow a one-size-fits-all approach obtaining suboptimal outcomes for many patients who fail to experience response or recovery.
View Article and Find Full Text PDFAnalysis of HAM-D Scores on Cognitive Functions and Heart Rate Variability in Patients with Major Depressive Disorder.
Niger Med J
January 2025
Department of Physiology, RUHS College of Medical Sciences, India.
Background: Previous research has shown that Major Depressive Disorder (MDD) is accompanied by severe impairments in cognitive and autonomic processes, which may linger even when mood symptoms recover. This study aimed to analyse the relationship between depression severity, as measured by the Hamilton Depression Rating Scale (HAM-D), and how it affects heart rate variability (HRV) and cognitive function in patients with Major Depressive Disorder (MDD).
Methodology: The cross-sectional study was conducted at RUHS College of Medical Sciences and Associated Hospitals, Jaipur, from July 2022 to January 2023 on 90 subjects having major depressive disorder (MDD) of either sex in the 20-40 age group using the Hamilton score for depression (HAM D), Heart Rate Variability (HRV) measurements, and a battery of cognitive tests.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!